2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Role of AI in Cancer
Artificial intelligence (AI) is a term used to describe a computer that performs tasks that are similar to those performed by humans. AI integration in cancer care could enhance diagnosis accuracy and speed, aid clinical decision-making, and result in better health outcomes. Machine learning and other AI technologies can significantly improve the current mode of anticancer drug research. Clinical treatment driven by AI has the potential to make a significant difference in eliminating health inequities, especially in low-resource settings. Researchers can collaborate in real-time and share knowledge virtually utilising an AI-based system method, potentially healing millions. AI also has the potential to revolutionize oncology by leveraging big data to propel cancer care into the twenty-first century and beyond.
- Cancer drug development
- AI and Cancer Imaging
- AI and Translational Oncology
- Clinical decision making and AI
- AI Limitations and Future Directions
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Thomas J Webster
Brown University, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Rihab Melliti
Aix en Provence General Hospital, FranceSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Anti-cancer nanomedicine in humans: A review and future directions
Thomas J Webster, Brown University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation